AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's i-body technology platform and pipeline of i-bodies; including its lead candidate for treating fibrotic diseases, in particular Idiopathic Pulmonary Fibrosis, AD-214.
A phase I human study is expected to begin in January 2020.
Price: 0.115 AUD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
Alto Capital's Tony Locantro says we're now seeing some long overdue volatility in the market and stocks falling to decent values. ''We had the Dow Jones up above 28,000, we had gold knocking on US$2000, both of those were extremely crowded trades''. ''We had the NASDAQ at stupid levels as well...
